Haemonetics (NYSE:HAE) Issues FY 2025 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.450-4.750 for the period, compared to the consensus earnings per share estimate of 4.400. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $93.25 on Thursday. The firm has a fifty day moving average of $83.59 and a two-hundred day moving average of $82.81. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of 37.91, a PEG ratio of 2.23 and a beta of 0.34. Haemonetics has a 52 week low of $70.74 and a 52 week high of $97.13.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. The company had revenue of $336.20 million during the quarter, compared to analysts’ expectations of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. Haemonetics’s revenue was up 10.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.85 EPS. As a group, equities research analysts predict that Haemonetics will post 3.95 EPS for the current year.

Wall Street Analysts Forecast Growth

HAE has been the subject of several research analyst reports. TheStreet cut shares of Haemonetics from a b- rating to a c+ rating in a report on Thursday, February 29th. StockNews.com cut Haemonetics from a buy rating to a hold rating in a report on Friday, March 22nd. Finally, Barrington Research reiterated an outperform rating and set a $105.00 price objective on shares of Haemonetics in a report on Friday, April 12th.

Insiders Place Their Bets

In other Haemonetics news, EVP Anila Lingamneni sold 2,305 shares of the company’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the transaction, the executive vice president now directly owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.79% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.